Post-earnings recap
Reported
Tue, Nov 12, 2024
EPS actual
$-0.30
EPS est.
$-0.45
EPS surprise
+33.33%
1-day move
+1.61%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Mirum Pharmaceutical's earnings report shows a positive surprise in EPS, which contributed to a 1.61% increase in stock price. The company did not disclose revenue figures, but management's comments suggest they are focused on future growth. Investors may view the EPS beat as a sign of operational efficiency, even without revenue guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | +33.33% |
| Revenue | N/A | N/A | N/A |
Overall, management remains focused on advancing their pipeline and is pleased with the EPS results. However, they did not provide specific revenue guidance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in product development and market expansion.